FDA to Speed Up Review of Novel CAR-T Cell Therapy for Rare Forms of Lymphoma and Leukemia

FDA to Speed Up Review of Novel CAR-T Cell Therapy for Rare Forms of Lymphoma and Leukemia The Food and Drug Administration (FDA) granted a fast track designation to an investigational CAR-T cell therapy, WU-CART-007, for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (LBL), according